EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment

Feifei Xin, Zhike Xie iD, Danyue Zhao iD, Lin Yang, Yiqun Wan iD, Zuwei Liu, Situ Xiong iD, Ying Zhang iD, Lei Feng, Hao Wan iD

Advanced Science · 2026-11 · 13 (63)

DOI: 10.1002/advs.77454 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 27.08.2026. Verfasst von Feifei Xin und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, Jiangxi, People's Republic of China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Butyrates, Immunosuppression Therapy. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province, Research Project of State Key Laboratory of Food Science and Resources.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Butyrate (BA) is essential for intestinal health, but its intestinal therapeutic applications are hindered by its malodorous nature, premature gastric absorption, and rapid intestinal metabolism. To address these challenges, an inodorous macromolecule β‐glucan‐BA (GLU‐BA) is synthesized via one‐step esterification, allowing for BA production in the intestine with burst yet gradual dynamics. After oral administration, GLU‐BA self‐assembles into nanomicelles, preventing premature gastric absorption. Upon reaching the intestine, endogenous esterases rapidly hydrolyze its ester bonds, triggering a burst BA release while exposing GLU, with the GLU subsequently metabolized by gut microbiota to gradually generate BA. Such sequential production enabled by a single oral administration of GLU‐BA ensures significant intestinal BA availability as early as 0.5 h post administration, lasting for at least 12 h. This leads to co‐achievement of prompt intervention and sustained therapeutic efficacy, as demonstrated in mouse models of ulcerative colitis and immunosuppression. Additionally, GLU‐BA restores gut microbiota dysbiosis, during which BA‐producing bacteria are enriched, reinforcing BA intestinal replenishment. With excellent biocompatibility (negligible toxicity after 366 days of daily oral administration), scalable synthesis (∼54 g per one‐pot reaction), and broad‐spectrum bioactivities of BA, GLU‐BA demonstrates to be a promising candidate for clinical applications in treating diseases associated with intestinal disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeButyratesImmunosuppression TherapyAnimalsAdministration, OralMiceGastrointestinal MicrobiomeDisease Models, AnimalMicellesHumans

Stichwörter der Autor:innen

butyrateimmunosuppressionnanomicelleself‐assemblyulcerative colitis

Substanzen

ButyratesMicelles

Autor:innen und Institutionen

  • State Key Laboratory of Food Science and Resources, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
  • Department of Food Science and Nutrition, The Hong Kong Polytechnic University, Hong Kong, People's Republic of China.
  • Research Institute for Future Food, The Hong Kong Polytechnic University, Hong Kong, People's Republic of China.
  • Department of Urology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.

ORCID-Profile: Zhike Xie, Danyue Zhao, Yiqun Wan, Situ Xiong, Ying Zhang, Hao Wan

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangxi Province
  • Research Project of State Key Laboratory of Food Science and Resources
  • Central Guidance Fund for Local Science and Technology Development in Jiangxi Province

Zitieren

APA

Xin, F., Xie, Z., Zhao, D., Yang, L., Wan, Y., Liu, Z., Xiong, S., Zhang, Y., Feng, L., & Wan, H. (2026). Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment. Advanced Science, 13(63). https://doi.org/10.1002/advs.77454

Vancouver

Xin F, Xie Z, Zhao D, Yang L, Wan Y, Liu Z, et al. Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment. Advanced Science. 2026;13(63). doi:10.1002/advs.77454

BibTeX
@article{Xin2026,
  author = {Xin, Feifei and Xie, Zhike and Zhao, Danyue and Yang, Lin and Wan, Yiqun and Liu, Zuwei and Xiong, Situ and Zhang, Ying and Feng, Lei and Wan, Hao},
  title = {Oral Nanomicelle‐Mediated Sequential Butyrate Production in the Intestine for Ulcerative Colitis and Immunosuppression Treatment},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {63},
  doi = {10.1002/advs.77454}
}
Kostenlos starten →